Since the discovery of cytostatic factor (CSF) 35 years ago, significant progress has been made in identifying molecular components of CSF activity and the mechanism of CSF-induced metaphase II arrest (CSF arrest). This short review focuses on recent discoveries in the field and discusses the implication of these results for a general picture of CSF establishment and release. One recent focus is on the cyclin E/Cdk2 pathway. The discovery of a downstream target for cyclin E/Cdk2, the spindle checkpoint protein Mps1, provides insight into how cyclin E/Cdk2 contributes to CSF arrest. The anaphase promoting complex/cyclosome (APC/C) inhibitor Emi2 is another recent focus of work in the field. It is now clear that not only is degradation of Emi2 critical for CSF release, but its abrupt accumulation during meiosis II (M II) is also required for the establishment of CSF arrest. Thus, by discrete pathways of APC/C inhibition operative during CSF arrest, the stability of cell cycle arrest in the egg appears to be reinforced by multiple mechanisms.
Introduction
The process by which an immature oocyte develops into a fertilizable gamete is known as oocyte maturation. In most animals, the mature oocytes or eggs are arrested in the meiotic cell cycle awaiting fertilization. Depending on the organism, this arrest can occur at different stages of meiosis and in vertebrates, unfertilized eggs are arrested at metaphase of meiosis II (M II). Over 35 years ago, Masui and Markert (1971) microinjected cytoplasm from a mature oocyte into embryonic blastomeres and found that injected blastomeres underwent cleavage arrest at the next mitosis, with a metaphase spindle cytologically similar to that in unfertilized eggs. They hypothesized that a specific factor from the cytoplasm caused this arrest and named the factor 'cytostatic factor' (CSF). Accordingly, M II arrest in the mature oocyte is termed CSF arrest.
As proposed by Masui and Markert (1971) , a molecule or activity mediating CSF arrest should meet several criteria: (1) appear during oocyte maturation with its highest level at M II; (2) cause metaphase arrest when microinjected into embryonic blastomeres; (3) be inactivated by elevated free calcium upon egg activation. Since then, extensive studies have been carried out in order to define molecular components of CSF activity. The first breakthrough in the field came in 1989 when Sagata et al. (1989) reported that the cellular homolog of the viral oncogene v-mos was sufficient for CSF activity in the blastomere injection assay. Subsequent studies from various groups have identified downstream components of the Mos-initiated cascade that leads to CSF arrest, including MEK1, MAPK, p90
Rsk and the spindle checkpoint proteins Bub1, Mad1 and Mad2 (reviewed in . These studies were made possible by development of a cell-free system for establishing CSF arrest. In this assay, cycling egg extracts prepared from activated eggs that have degraded endogenous Mos arrest in mitosis with CSF-like features upon addition of Mos or other CSF components (Bhatt and Ferrell, 1999) . Studies from this and other groups have found that cyclin E/Cdk2 can also establish metaphase arrest independently of the Mos pathway in cycling egg extracts (D'Angiolella et al., 2001; Tunquist et al., 2002) , and this pathway also involves a spindle checkpoint protein, Mps1, which is not required for Mos-induced arrest . Recently, an F-box protein, Emi1, was proposed as a direct inhibitor of Cdc20-APC/C activation in CSFarrested Xenopus egg extracts (Reimann and Jackson, 2002) , but later studies showed that Emi1 is degraded during oocyte maturation and is unlikely to regulate APC/C activity during CSF arrest (Ohsumi et al., 2004; Grimison and Maller, unpublished data) . However, a newly discovered Emi-related protein 1 (Erp1, also called Emi2) was identified that crossreacts with some antibodies to Emi1 (Tung et al., 2005 ). Emi2 appears to be required for establishment and maintenance of CSF Liu et al., 2006) , and its degradation or removal leads to CSF release (Liu and Maller, 2005; Rauh et al., 2005; Hansen et al., 2006) .
Because our understanding of CSF arrest has been greatly increased owing to the identification of the cyclin E/ Cdk2 and Emi2 pathways, this review will discuss primarily new data and its implications for the current model of CSF arrest, focusing mainly on results from the Xenopus system.
Establishment of CSF arrest
This review will summarize results on two pathways contributing to CSF establishment. One of the pathways involves cyclin E/Cdk2. In resting oocytes, cyclin E/Cdk2 is present at a very low level, but increases markedly before M II (Rempel et al., 1995) . To understand the mechanism of cyclin E/Cdk2-induced APC/C inhibition and CSF arrest, we first determined if cyclin E/ Cdk2 causes direct inhibition of the APC/C, or instead blocks activation of the APC/C, as is characteristic of the spindle assembly checkpoint. Studies showed that addition of Cdc20, an activator of the APC/C, was able to overcome cyclin E/Cdk2-induced metaphase arrest, suggesting inhibition is indirect . Recent studies have focused on the spindle checkpoint protein kinase Mps1, as it has been reported to be a cyclin E/Cdk2 substrate for centrosome duplication (Fisk and Winey, 2001) and is required for the spindle checkpoint (Abrieu et al., 2001) . It was found that depletion of Mps1 from cycling egg extracts had no effect on CSF arrest with Mos, but blocked constitutively active cyclin E/Cdk2-induced metaphase arrest. This block could be rescued by wild type, but not kinase-dead Mps1 , suggesting that the kinase activity of Mps1 is required for CSF arrest by cyclin E/Cdk2 but not by Mos. It was noted that microinjection of morpholino antisense oligonucleotides against either cyclin E or Mps1 into oocytes did not block the establishment of CSF arrest, indicating that the cyclin E/Cdk2/Mps1 pathway is not required to establish CSF arrest. Although the cyclin E/Cdk2-Mps1 pathway is not required for CSF arrest, evidence showed that even in the presence of UO126, constitutively active cyclin E/Cdk2 significantly stabilized the level of cyclin B2 in oocytes compared to controls , suggesting that the cyclin E/Cdk2 pathway may contribute to stabilizing cyclin B in addition to other pathways to achieve full inhibition of APC/C activity and CSF arrest. Moreover, in order for CSF release to occur in response to elevated free calcium, cyclin E/Cdk2 must be inactivated by dephosphorylation of tyrosine (Tyr) 15 in Cdk2 (D'Angiolella et al., 2001; Grimison et al., 2006) .
The other pathway contributing to CSF arrest involves the newly identified F-box protein Emi2 , whose degradation has been shown to be critical for CSF release (Liu and Maller, 2005; Rauh et al., 2005; Hansen et al., 2006) . To understand its role in CSF establishment, Liu et al. (2006) determined the levels of Emi2 during oocyte maturation, fertilization and subsequent mitotic cell cycles after fertilization; like cyclin E/Cdk2, Emi2 levels are very low in resting oocytes, and rise dramatically before M II. As reported previously, Emi2 is completely degraded after fertilization, but it is re-synthesized in subsequent mitotic cell cycles to a level only about 20% of that present during CSF arrest. Interestingly, depletion of Emi2 from cycling extracts only slightly delayed cell cycle progression, whereas raising the level of Emi2 in the extracts to that present during CSF arrest led to metaphase arrest. It thus appears that a high level of Emi2 is uniquely present in CSF-arrested eggs, and this level of Emi2 may be key for sustained inhibition of APC/C activity during CSF arrest. Antisense ablation of Emi2 from maturing oocytes blocked progression through M II and establishment of CSF arrest, leading to exit from meiosis; co-injection of Emi2 antisense oligonucleotides and recombinant Emi2 rescued the arrest, indicating that Emi2 is required for both establishment and maintenance of CSF arrest . Similar results were also reported for mouse oocytes (Madgwick et al., 2006; Shoji et al., 2006) . Despite the fact that Emi2 is generally regarded as an APC/C inhibitor, the mechanism of this inhibition is unclear, although a recent report indicates recombinant Emi2 binds to Cdc20 in vitro (Shoji et al., 2006) .
To summarize the mechanism of CSF establishment, a simplified model is shown in Figure 1 . Three pathways contribute to CSF arrest including Mos/MAPK, Emi2 and the cyclin E/Cdk2 pathway. The suppression of S phase by only partial loss of APC/C activity after anaphase I is a primary function of the Mos/MAPK pathway, as it is fully active in anaphase I whereas Emi2 and cyclin E/Cdk2 are only synthesized 2 h later (Rempel et al., 1995; Liu et al., 2006) . Establishment of stable CSF arrest may occur only after full APC/C inhibition is promoted by the action of all three pathways. The three pathways have been studied independently so far under various experimental conditions, but whether there is any interaction between these pathways in vivo is an important question that remains to be investigated.
Maintenance of CSF arrest
As discussed above, three pathways contribute to establishment of CSF arrest, but are they also involved in CSF maintenance? Components needed to establish CSF arrest during meiotic progression might not be required to maintain the arrest. For example, inhibition of the Mos/MAPK pathway by UO126 in CSF egg extracts does not cause CSF release (Reimann and Pathways of CSF arrest J Liu et al Jackson, 2002; Tunquist et al., 2002) , although UO126 treatment has been reported to be sufficient to trigger CSF release in intact mouse eggs (Phillips et al., 2002) . In the Xenopus system, immunodepletion of downstream components of the Mos/MAPK pathway confirmed that p90
Rsk , Bub1 and Mad2 are not required for maintenance of CSF arrest, although all are required for establishment of arrest by Mos in cycling egg extracts (Bhatt and Ferrell, 1999; Sharp-Baker and Chen, 2001; Tunquist et al., 2002 . For the cyclin E/Cdk2 pathway, it has been found that complete inhibition of cyclin E/Cdk2 by p27 Xic1 , or even a combination of p27
Xic1 and UO126 did not cause CSF release (Tunquist et al., 2002) , suggesting that these components of CSF are also not required for maintenance of the arrest. In addition, Abrieu et al. (2001) reported that immunodepletion of Mps1 did not cause CSF release. The Emi2 pathway, however, appears to be required for both establishment and maintenance of CSF arrest, as immunodepletion of Emi2 from CSF extracts caused spontaneous CSF release Liu et al., 2006) . Both Mad2 and Emi2 clearly act to prevent APC/C activation by Cdc20, and it is expected that depletion of either them would have a similar effect to relieve APC/C inhibition and promote anaphase. However, only depletion of Emi2, not Mad2, causes CSF release in the absence of calcium, suggesting that Emi2 is a more important physiological APC/C inhibitor in eggs Schmidt et al., 2005; Liu et al., 2006) . This is consistent with the result that even the combination of constitutively active CaMK II and Plx1 cannot overcome Mad2-imposed APC/C inhibition in extracts, whereas the same kinase combination is sufficient to trigger Emi2 degradation and CSF release (Liu and Maller, 2005) . Another possibility is that the Mos/MAPK and cyclin E/Cdk2 pathways converge on and execute APC/C inhibition via Emi2, as proposed by Schmidt et al. (2006) . This is an attractive model, but more studies are needed to evaluate this possibility.
Release of CSF arrest by calcium
As originally proposed by Masui and Markert (1971) , a CSF component or molecule should not only cause metaphase arrest in a blastomere, but also be inactivated by elevated free calcium upon egg activation. Recently, three groups independently revealed a major mechanism of CSF release upon fertilization (Liu and Maller, 2005; Rauh et al., 2005; Hansen et al., 2006) . It was found that elevated intracellular calcium levels activate CaMK II (Lorca et al., 1993) , which then phosphorylates threonine (Thr) 195 of Emi2 to generate a polo box-binding domain for Plx1 . Subsequent phosphorylation at the N-terminus by Plx1 renders Emi2 a better substrate for the SCF uniquitin ligase complex, which degrades Emi2 and relieves Emi2-imposed inhibition of the APC/C, and hence causes CSF release (Liu and Maller, 2005; Rauh et al., 2005; Hansen et al., 2006) . However, is Emi2 the only factor that needs to be degraded/inactivated for CSF release? Previously, it has been reported that inactivation of Cdk2 by Tyr 15 phosphorylation is required for CSF release (D'Angiolella et al., 2001) . Recent studies in this laboratory confirmed this result and suggest that inactivation of Mps1 is also required for CSF release . CSF extracts supplemented with kinase-dead Mps1 released normally upon the addition of calcium, whereas release of wild-type Mps1-supplemented extracts was significantly delayed; the extent of the delay was correlated with the rate of dephosphorylation and inactivation of the added Mps1 . It has also been noted that Mps1 levels are stabilized by cyclin E/Cdk2, and this observation prompts the tempting hypothesis that sequential inactivation of Mps1 is required for CSF release. In the case of the Mos/MAPK pathway, Mos is dephosphorylated and degraded by an unidentified ubiquitination mechanism 30-40 min after calcium addition (Watanabe et al., 1991) . The Mos/MAPK/p90
Rsk pathway is thus kinase active even after calcium-induced CSF release, suggesting that release of APC/C inhibition from this pathway by calcium is mediated by action on a downstream element of the pathway, possibly Mad1 or Mad2.
Conclusion
Since the discovery of CSF activity over 30 years ago, our understanding of the molecular mechanism of CSF arrest has increased significantly. With the discovery of Emi2 and its role in CSF release, a clearer picture of CSF arrest is beginning to emerge. However, to fully understand the mechanism of CSF from establishment to release, some important questions remain to be answered. For example, whereas Emi2 is clearly an important component of CSF, the exact mechanism of its inhibition of APC/C activity is unknown, except for one report that Emi2 interacts with Cdc20 in vitro (Shoji et al., 2006) . As its depletion from CSF extracts causes CSF release, whereas the removal/inactivation of other components does not, even though they may be required for establishment of CSF arrest, it is possible that all pathways converge on Emi2 to inhibit APC/C activity in CSF. Previous results showed that addition of cycloheximide immediately after germinal vesicle breakdown (which would inhibit synthesis of Emi2 and cyclin E) led to exit from M I and degradation of endogenous Mos (Roy et al., 1996) . This M phase exit was delayed by coinjection of recombinant Mos sufficient to markedly activate the MAPK pathway (Roy et al., 1996) . This result indicates that the Mos/MAPK pathway alone may be sufficient to suppress S phase after anaphase I but is not enough to maintain M phase during meiosis II and a prolonged CSF arrest. Whether the abrupt appearance of Emi2 and cyclin E/Cdk2 2 h after anaphase I is activated by the Mos/MAPK pathway is an attractive possibility that merits further investigation. In any case, it is clear that multiple redundant pathways for APC/C inhibition contribute to the stability of metaphase arrest by CSF (Figure 1 ).
